CagriSema is Novo Nordisk's investigational once-weekly injection that pairs cagrilintide, an amylin analog, with semaglutide 2.4 mg. As of October 2026 it is under FDA review, not approved. TelosRX's clinical team answers the questions people search most.
CagriSema gets a lot of headlines. Most of them skip the parts you actually need: what it is, what the trials found, and whether you can get it.
This Q&A pulls the most-searched CagriSema questions into one place. Each answer is sourced and written in the plain, careful tone of the pharmacists who review TelosRX protocols. No hype, no promises.
CagriSema at a Glance
- What it is: A fixed combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, given once a week.
- Who makes it: Novo Nordisk, the maker of Wegovy and Ozempic.
- FDA status: Investigational. Novo filed for approval in December 2025 and has said a US decision is expected in late 2026.
- Studied for: Chronic weight management in adults with obesity, or overweight with a weight-related condition.
- Available at TelosRX? No. CagriSema is only available inside clinical trials right now.
What Is CagriSema, in Plain English?
CagriSema is two hormone-mimicking drugs in one weekly shot. Semaglutide copies GLP-1, a gut hormone that signals fullness. Cagrilintide copies amylin, a hormone your pancreas releases alongside insulin.
Both hormones talk to appetite centers in the brain. They just use different receptors. The idea is that hitting both pathways adds up to a stronger fullness signal than either one alone.
If amylin is new to you, our guide to amylin analogs, from Symlin to CagriSema walks through the whole drug class.
How Is CagriSema Different From Semaglutide Alone?
Semaglutide works through one pathway: the GLP-1 receptor. CagriSema adds a second pathway through amylin receptors. That's the core difference.
Amylin slows how fast your stomach empties. It also dampens the urge to keep eating after a meal starts. Adding it to semaglutide is meant to deepen the fullness effect without simply raising the semaglutide dose.
In REDEFINE 1, the trial included a semaglutide-only arm and a cagrilintide-only arm. That design let researchers see what the combination added beyond each piece.
What Did the Main CagriSema Trials Find?
Two phase 3 trials, both published in the New England Journal of Medicine in 2025, form the core of the evidence. Here's what each reported over 68 weeks.
| Trial | Who enrolled | Mean body-weight change (CagriSema vs placebo) | GI side effects (CagriSema vs placebo) |
|---|---|---|---|
| REDEFINE 1 | 3,417 adults with obesity or overweight plus a related condition, no diabetes | −20.4% vs −3.0% | 79.6% vs 39.9% |
| REDEFINE 2 | 1,206 adults with obesity or overweight and type 2 diabetes | −13.7% vs −3.4% | 72.5% vs 34.4% |
Sources: Garvey et al., REDEFINE 1, NEJM 2025 and Davies et al., REDEFINE 2, NEJM 2025.
These are trial averages, not predictions for any one person. Everyone in both trials also followed a lifestyle program. Individual results vary.
Is CagriSema FDA-Approved?
Not as of October 2026. Novo Nordisk submitted its application in December 2025, based mainly on the REDEFINE program. The company has said it expects a US decision in the fourth quarter of 2026.
FDA decisions can land early, late, or come with requests for more data. So read any article, including this one, as a snapshot. The FDA's Drugs@FDA database is the place to confirm current status.
Cagrilintide on its own is also not FDA-approved. It has only been studied as an investigational drug.
How Does CagriSema Compare With Tirzepatide?
Novo ran a head-to-head trial against tirzepatide 15 mg, called REDEFINE 4. In February 2026, the company announced that CagriSema did not meet its primary goal of showing it was non-inferior to tirzepatide over 84 weeks.
Both drugs still produced large average weight reductions in that open-label trial. Tirzepatide's average was higher, according to Novo's announcement.
We cover the two mechanisms in more depth in cagrilintide vs tirzepatide.
What Side Effects Were Reported?
The pattern looks a lot like other GLP-1 medicines. Stomach and gut effects were the most common, and most were mild to moderate and temporary in both trials.
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
The trials used slow dose increases to help the gut adjust. For a deeper look at the amylin side of things, see cagrilintide side effects, answered.
What Dose Was Studied?
The phase 3 trials used cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly. Participants reached that maintenance dose gradually over several months.
That's a trial protocol, not a recommendation. If CagriSema is approved, the FDA label will set official dosing. Any real-world use would be subject to medical approval by a licensed provider.
Can You Get CagriSema Today?
Only through a clinical trial. Novo Nordisk is still running CagriSema studies. You can search active ones on ClinicalTrials.gov.
Be cautious with anything sold online as "CagriSema" or "cagrilintide." Neither is an FDA-approved drug. Products sold as research chemicals aren't made to pharmacy standards and may not contain what the label says.
TelosRX does not offer CagriSema or cagrilintide.
What Are the Options While CagriSema Is Under Review?
Several GLP-1 medicines are available today. These include FDA-approved brands and, where appropriate, compounded options. A provider decides what fits your health history.
Want to see what's available now? Compare TelosRX GLP-1 options, including tirzepatide. Every prescription is subject to medical approval by a licensed provider. Compounded medications are not FDA-approved.
How Does TelosRX Review GLP-1 Requests?
TelosRX is an asynchronous telehealth service. You fill out a secure online intake on your own schedule. There's no live video appointment to book.
A licensed provider reviews your history, goals, and any labs. If a medication is appropriate, they may issue a prescription. If not, they'll explain why. You can message your care team any time.
Frequently Asked Questions
Is CagriSema a GLP-1 drug?
Partly. CagriSema contains semaglutide, which is a GLP-1 receptor agonist, plus cagrilintide, which is an amylin analog. So it acts on two hormone systems instead of one. That dual action is why it's often described as a GLP-1 and amylin combination rather than a pure GLP-1 medicine.
When will CagriSema be available?
No one can say for sure. Novo Nordisk filed with the FDA in December 2025 and has said it expects a US decision in the fourth quarter of 2026. Even after an approval, pharmacy availability and insurance coverage usually take additional time. Until then, CagriSema is only available through clinical trials.
Is CagriSema stronger than Wegovy?
REDEFINE 1 reported a larger average body-weight reduction with CagriSema than with semaglutide alone over 68 weeks. That suggests the added amylin analog contributed. Trial averages don't predict individual results, and CagriSema also had high rates of stomach side effects. A provider weighs these trade-offs case by case.
Is CagriSema a pill or an injection?
The CagriSema studied in the REDEFINE phase 3 trials is a once-weekly injection under the skin. It combines cagrilintide 2.4 mg and semaglutide 2.4 mg. Any future forms would need their own studies and FDA review before they could reach patients.
Does CagriSema cause muscle loss?
Any large weight reduction can include some lean mass, and that's true across GLP-1 medicines. Published CagriSema data on body composition is still limited. Most clinicians stress protein intake and resistance training during any medical weight-loss program. Your provider can help you plan for this.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.